Rothschild & Co Initiates Coverage of West Pharmaceutical Services (WST) with Buy Recommendation

Rothschild & Co initiated coverage on West Pharmaceutical Services (WST) with a Buy recommendation on September 15, 2025, projecting an average one-year price target of $320.57, which implies a 24.48% upside from its $257.54 closing price. This positive outlook is underpinned by projected annual revenue growth of 7.80% to $3,191MM and a non-GAAP EPS of $8.80. Despite a slight decrease in the number of institutional owners and total shares held, the average portfolio weight dedicated to WST increased by 11.15%, and a put/call ratio of 0.57 indicates a generally bullish sentiment among investors.

Analysis

Rothschild & Co's initiation of coverage on West Pharmaceutical Services (WST) with a 'Buy' recommendation provides a significant positive catalyst, supported by an average analyst price target suggesting a 24.48% upside from its recent closing price. This bullish outlook is underpinned by solid fundamental projections, including an expected 7.80% increase in annual revenue to $3,191MM and non-GAAP EPS of $8.80. While overall institutional ownership shows a slight contraction, with a 0.61% decrease in the number of funds and a 0.51% reduction in total shares held, the narrative is complicated by a substantial 11.15% increase in the average portfolio weight dedicated to WST. This divergence suggests that while some institutions are exiting, those remaining or entering are doing so with higher conviction. This is exemplified by specific fund movements: POLAR CAPITAL significantly increased its stake by 25.70%, whereas Bank of New York Mellon and Brown Advisory both reduced their positions. Further reinforcing the positive sentiment, the options market indicates a bullish outlook with a put/call ratio of 0.57.

Key Decisions for Investors

• The new 'Buy' rating and 24.48% price target upside, backed by strong revenue and EPS growth forecasts, suggest investors should consider the stock's bullish potential.
• Monitor the divergent institutional flows; while the increase in average portfolio weight is positive, significant selling by firms like Bank of New York Mellon and Brown Advisory warrants attention as a potential risk factor.
• Given the bullish put/call ratio of 0.57, investors could view this as confirmation of positive market sentiment and a factor supporting the analyst's optimistic thesis.